Stephan Schann

Company: Domain Therapeutics

Job title: Chief Scientific Officer

Seminars:

Leveraging Effective Models for Anti-CCR8 Antibody to Inform First In- Human Clinical Trials 1:15 pm

Developing and optimizing novel methods to identify endogenous and synthetic ligands acting on GPCRs to allow for the design of targeted GPCR therapies Application of the novel Gz-Enhanced Signal Transduction assaY (GzESTY) for identifying orphan GPCR ligands in complex tissue extracts and compound libraries Development of novel screening assays for the rapid identification of inverse…Read more

day: Conference Day Two